# Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

> **NCT02296229** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 220 (estimated)

## Conditions studied

- Adenocarcinoma of the Prostate
- Stage III Prostate Cancer

## Interventions

- **RADIATION:** stereotactic body radiation therapy
- **OTHER:** quality-of-life assessment
- **OTHER:** laboratory biomarker analysis
- **DRUG:** androgen deprivation therapy

## Key facts

- **NCT ID:** NCT02296229
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-01-27
- **Primary completion:** 2026-01-27
- **Final completion:** 2027-01-27
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296229, "Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02296229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*